Any current/future new fundraising through debt or equity?

The company plans to keep CAPEX for FY ‘26 between Rs. 70 to 80 crores, primarily for pharma capacity expansion, building completion, and printing enhancement. No explicit mention of new fundraising through debt or equity in the transcript. The management indicates a cautious but confident approach towards investments, especially in pharma, with ongoing land acquisitions for future expansions. There is no direct statement about raising funds via debt or equity at present or in near future during the call.

Any current/future capex/capital investment/strategic investment?

FY '26 CAPEX is guided between Rs. 70 to 80 crores, partly for pharma and printing expansion. Pharma segment is getting Rs. 20-25 crores for land acquisition and building completion at Sultanpur. Existing Sultanpur facility capacity being expanded from 1,500 tons to 3,000 tons per annum by March 2026. New land (~2.5 acres) acquired adjacent to Sultanpur for future pharma expansion beyond 3,000 tons capacity. Additional machines (injection molding, printing) being added; 5 new injection molding machines to arrive by June. Printing capacity increased by 70% with investments of over Rs. 25 crores

Future growth expectations in sales/revenue/volumes?

Pharma segment expected to see 2.3x to 3x growth in next financial year, targeting Rs. 30+ crores in FY26 and Rs. 50+ crores in FY27. Pharma volumes aimed at 3,000 tons per annum by end of FY26, with revenue potential of Rs. 90-100 crores. Paint segment growth in FY26 expected to reach double digits (~10%) driven by capacity expansions and increased IML adoption by Asian Paints. Food & FMCG segment targeting 15%-20% growth in FY26 due to enhanced printing capacity and new client additions. Overall company volume growth target for FY26 is around 15%. EBITDA per kg expected to improve,

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects at least a 15% volume growth in FY ‘26 with EBITDA per kg targeting between Rs. 41 and Rs. 42. (Page 12) EBITDA per kg is anticipated to rise toward Rs. 42-43 in the next quarters, driven by higher margin segments like Pharma and Food. (Page 9) Pharma division, which reached breakeven in Q4 FY ‘25, is expected to grow from Rs. 11 crores to Rs. 30-35 crores in FY ‘26 and potentially Rs. 50+ crores in FY ‘27, contributing significantly to EBITDA margin improvement. (Pages 6, 4) Paint segment growth is expected to improve to double-digits (~10%) in FY ‘26 due to enhanced capac

IN US

Sale is live|00:00:00left today

Mold-Tek Packaging LtdQ1 FY25Industrial Products

Mold-Tek Packaging Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹702P/E: 32.3Market Cap: ₹2.3K CrSector: Industrial Products

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Pharma segment expected to see 2.3x to 3x growth in next financial year, targeting Rs. 30+ crores in FY26 and Rs. 50+ crores in FY27.
→Pharma volumes aimed at 3,000 tons per annum by end of FY26, with revenue potential of Rs. 90-100 crores.
→Paint segment growth in FY26 expected to reach double digits (~10%) driven by capacity expansions and increased IML adoption by Asian Paints.
→Food & FMCG segment targeting 15%-20% growth in FY26 due to enhanced printing capacity and new client additions.
→Overall company volume growth target for FY26 is around 15%.
→EBITDA per kg expected to improve, with internal targets around Rs. 41-42 per kg in FY26, driven by pharma and food/FMCG segments.
→Capacity utilization improving in key plants (up to 75-80% in April).
→Export opportunities in pharma expected to start contributing within 1-2 years, including US and European markets.

Margin guidance

Category 1

→The company expects at least a 15% volume growth in FY ‘26 with EBITDA per kg targeting between Rs. 41 and Rs. 42. (Page 12)
→EBITDA per kg is anticipated to rise toward Rs. 42-43 in the next quarters, driven by higher margin segments like Pharma and Food. (Page 9)
→Pharma division, which reached breakeven in Q4 FY ‘25, is expected to grow from Rs. 11 crores to Rs. 30-35 crores in FY ‘26 and potentially Rs. 50+ crores in FY ‘27, contributing significantly to EBITDA margin improvement. (Pages 6, 4)
→Paint segment growth is expected to improve to double-digits (~10%) in FY ‘26 due to enhanced capacities and increased IML adoption by Asian Paints and ABG. (Page 5)
→Overall EBITDA growth will benefit from strong growth and high margins in Food & FMCG and Pharma segments, along with stabilized paint segment performance. (Pages 9, 7)
→PAT had a slight 9% dip last year but future outlook is positive given operational improvements and product mix. (Page 3)

3 more insights locked — sign up free to unlock

Fundraise plans

→The company plans to keep CAPEX for FY ‘26 between Rs. 70 to 80 crores, primarily for pharma capacity expansion, building completion, and printing enhancement.
→No explicit mention of new fundraising through debt or equity in the transcript.
→The management indicates a cautious but confident approach towards investments, especially in pharma, with ongoing land acquisitions for future expansions.
→There is no direct statement about raising funds via debt or equity at present or in near future during the call.

Order book

The transcript from the Mold-Tek Packaging Limited conference call on May 19, 2025, does not explicitly mention details about the current or expected order book or pending orders. However, some relevant insights include: - The Pharma division showed strong growth, with a 3x turnover increase in Q4 and a base established for future quarters, indicating a healthy order inflow. - Capacity utilization improvements at ABG and various plants (e.g., Satara running at 75%-80% capacity in April) suggest increasing order volumes. - Asian Paints has progressively shifted brands into IML, enhancing order volumes for Mold-Tek across multiple plants. - The company expects double-digit growth in the Paint segment and 15%-20% growth in the Food and FMCG segment for FY26, implying a positive order pipeline. - New client additions in Food & FMCG (e.g., Marico, Mankind) also indicate growing demand. No explicit quantitative orderbook or pending order figures were disclosed.

Capex plans

Yes

→FY '26 CAPEX is guided between Rs. 70 to 80 crores, partly for pharma and printing expansion.
→Pharma segment is getting Rs. 20-25 crores for land acquisition and building completion at Sultanpur.
→Existing Sultanpur facility capacity being expanded from 1,500 tons to 3,000 tons per annum by March 2026.
→New land (~2.5 acres) acquired adjacent to Sultanpur for future pharma expansion beyond 3,000 tons capacity.
→Additional machines (injection molding, printing) being added; 5 new injection molding machines to arrive by June.
→Printing capacity increased by 70% with investments of over Rs. 25 crores in the previous financial year.
→ABG (Aditya Birla Group) capacity enhanced with Brownfield expansion, operating fully from March-April 2025.
→Strategic focus on pharma growth: expecting 2.3x to 3x pharma revenue growth next financial year; exploring export opportunities.
→IML facility expanded across Asian Paints' plants, supporting growth.
→CAPEX carefully controlled to Rs. 70-80 crore for FY ‘26 despite higher spend in FY ‘25 (~Rs. 140 crores).

How does Mold-Tek Packaging Ltd rank vs peers in Industrial Products?

Pro feature

1Mold-Tek Packaging Ltd

Rev 3Mar 1

See full Industrial Products sector rankings

Want more stocks like Mold-Tek Packaging Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio